×

Get the Best GovCon News Straight to your Inbox

Articles

What Are the Top Moderna Government Contract Awards?

What Are the Top Moderna Government Contract Awards?

Photo by pcruciatti from shutterstock.com

Moderna is a top U.S. government contractor in the pharmaceutical and biotechnology industry. It quickly rose to success in federal contracting as a pioneer in developing new mRNA technology and therapeutics for treating diseases. The company has been at the forefront since the fight against the COVID-19 pandemic, securing numerous lucrative contracts. Know the top Moderna government contract awards here!

1. U.S. Government’s COVID-19 Vaccine Deal, $1.5 Billion

Moderna's development and production of COVID-19 vaccine mRNA-1273; Moderna government contract awards

Photo by Serhii Yevdokymov from shutterstock.com

  • Year: 2020
  • Contracting activity: U.S. government

In August 2020, the U.S. government awarded Moderna a $1.2 billion contract award with a potential ceiling value of $1.5 billion to produce 100 million doses of the COVID-19 vaccine mRNA-1273.

Moderna could have received a maximum of $8 billion if all government options were exercised to produce an additional 400 million doses. However, the required volume at the agreed price of $16 per dose was not in line with what Moderna could produce. As a part of the government’s COVID-19 campaign. Americans received the government-owned vaccines at no cost and only paid for healthcare professionals who administered the vaccine.

2. U.S Army’s COVID-19 Vaccine Production Contract, $3.3 Billion

Department of Defense's COVID-19 Vaccine Production Contract, $3.3 Billion; COVID-19 prevention

Shutterstock / Photo Contributor: Jacob Lund

  • Year: 2021
  • Contracting activity: U.S. Army Contracting Command
  • Contract type: Contract modification
  • Contract duration: 1 year (ended in March 2022)

In June 2021, Moderna secured a $3.3 billion contract award from the U.S. Army. Under the modification contract, Moderna was to produce 200 million drug doses of the double-shot vaccine, SARS-CoV-2 mRNA-1273, by March 2022. The funding included the vaccine’s research and development and evaluation.

This initiative was in place of the Biden administration’s goal to have at least 70% of American adults partially vaccinated before the first week of July.

3. U.S. Department of Defense’s Additional COVID-19 Vaccine, $1.97 Billion

U.S. Department of Defense Awards Moderna $1.97 Billion COVID-19 Vaccine Contract to be done in Massachusetts sites; COVID response

Photo by peterschreiber.media from shutterstock.com

  • Year: 2020
  • Contracting activity: U.S. Army Contracting Command
  • Contract type: Modification contract
  • Contract duration: 6 months (ended in June 2021)

In December 2021, Moderna won a $1.9 billion modification contract award from the Department of Defense to provide additional 100 million COVID-19 vaccine doses. The work was done in Massachusetts, with an expected delivery time of June 2021.

The FDA and Health Canada granted Moderna’s vaccines emergency use authorization (EUA) in the United States and Canada, respectively, in December. This allowed citizens 18 years of age and older to receive the vaccine.

4. U.S. Government’s Bivalent COVID-19 Booster Vaccine Supply, $1.74 Billion

Manufacturing of Moderna Bivalent COVID-19 Booster Vaccine Supply, $1.74 Billion; COVID response

Photo by Wetzkaz Graphics from shutterstock.com

  • Year: 2022
  • Contracting activity: U.S. Army Contracting Command
  • Contract type: Firm-fixed-price
  • Contract duration: 2 years (ends in March 2024)

In July 2022, the U.S. government awarded Moderna a $1.74 billion contract award to produce and deliver 66 million doses of Moderna’s bivalent COVID-19 booster vaccine, ensuring enough supply of upgraded boosters for winter.

The vaccine booster candidate is called mRNA-1273.222, which is a bivalent booster that contains Spikevax and the Omicron BA.4/5 strain mRNA. It specifically targets the viral omicron variant, which has been predominant in the country since December of the previous year. The contract option allows the government to receive a maximum of 234 million doses in the future.

5. U.S Army’s Moderna Vaccine Supply of SARS-CoV-2 mRNA-1273, $1.65 Billion

Moderna's agreement with the U.S. Army for the Vaccine Supply of SARS-CoV-2 mRNA-1273, $1.65 Billion

Photo by anon_tae from shutterstock.com

  • Year: 2021
  • Contracting activity: U.S. Army Contracting Command
  • Contract type: Modification contract
  • Contract duration: 5 months (ended in July 2021)

In February 2021, Moderna secured a $1.65 billion modification contract award from the U.S. Army to provide the second batch of 100 million SARS-CoV-2 mRNA-1273 doses, delivering its confirmed order commitment to 300 million doses. The following batch of delivery was scheduled for July, which was originally expected in September to meet the supply target.

6. U.S. Government’s Warp Speed Project, $1.53 Billion

U.S. Government's Warp Speed Project, $1.53 Billion; National Institutes of Allergy and Infectious Diseases

Photo by Leonard Zhukovsky from shutterstock.com

  • Year: 2020
  • Contracting activity: U.S. Army Contracting Command
  • Contract type: Firm-fixed-price
  • Contract duration: 2 years (ended in March 2022)

In August 2020, Moderna received a $1.53 billion firm-fixed-price contract award from the U.S. Army. Under the Warp Seed contract, Moderna produced 100 million drug doses of the SARS-CoV-2 mRNA-1273 vaccine. Warp Seed is a project run by the White House to accelerate the development of Covid vaccines, diagnostic treatments, and drugs.

Moderna has been developing the mRNA-1273 vaccine with the National Institute of Allergy and Infectious Diseases when it received a fund of $1 billion. The work was done in Cambridge, Massachusetts, with a delivery date of March 2022.

7. Biomedical Advanced Research and Development Authority’s (BARDA) Vaccine Development Contract, $483 Million

Biomedical Advanced Research and Development Authority's (BARDA) Vaccine Development Contract, $483 Million

Photo by Leonard Zhukovsky from shutterstock.com

  • Year: 2020
  • Contracting activity: Biomedical Advanced Research and Development Authority (BARDA)

In April 2020, Moderna received a $483 million contract award from the Biomedical Advanced Research and Development Authority (BARDA) to escalate the mRNA-1273 vaccine’s development for COVID-19. BARDA funded the vaccine from its clinical development, advancement, and manufacturing in 2020 to its phase I clinical trial and FDA approval. Moderna planned to hire over 150 new members to increase its manufacturing capacity, manage its scale-up process, and support its full clinical development.

About Moderna

In the fight against the pandemic, Moderna has secured many government contracts bringing into focus COVID-19 vaccines and boosters as its commercial products. The company’s long-term partnership with the government enabled it to develop vaccines rapidly in high-quality, remaining at low cost in the U.S. and worldwide. Moderna leaders and executives have supported the company’s efforts as it makes mRNA medications a reality for humanity.

 

GovCon Wire Logo

Sign Up Now! Potomac Officers Club provides you with Daily Updates and News Briefings about Articles

Category: Articles